Gabriel Pardo, MD
Enriched profileDirector of the Oklahoma Medical Research Foundation Multiple Sclerosis Center of Excellence · Oklahoma Medical Research Foundation
Gabriel Pardo is Director of the Oklahoma Medical Research Foundation Multiple Sclerosis Center of Excellence at Oklahoma Medical Research Foundation. OpenAlex indexes 111 publications with 2,629 citations (h-index 27); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Gabriel Pardo, M.D., is Director of the Oklahoma Medical Research Foundation Multiple Sclerosis Center of Excellence. The public record shows 111 publications with 2,629 citations (h-index 27), centered on Multiple Sclerosis Research Studies, Chronic Lymphocytic Leukemia Research, Polyomavirus and related diseases. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 32 companies.
- Most recent indexed publication: 2026 · Advances in therapy
- Top research focus: Multiple Sclerosis Research Studies
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 32 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 13 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 47.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Skeletal Muscle Aging and Responsiveness in Aged People With MS
Sponsor: Oklahoma Medical Research Foundation
- Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Industry payments
Updated 16 Oct 2026
32 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- EMD Serono, Inc.Program year202598 payments$155,760openpaymentsdata.cms.gov ↗
- Genentech USA, Inc.Program year202558 payments$58,721openpaymentsdata.cms.gov ↗
- TG Therapeutics, Inc.Program year202566 payments$51,052openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
91%CD20-directed Cytolytic Antibody89.7%Ocrelizumab100%Kesimpta Pen0%Part D + Part B<11 patientsOther immunostimulants0.4%Copaxone72%Glatiramer Acetate16%Glatopa12%Part D<11 patients+ 5 more classes in this area
Nervous system
4.3%Gabapentinoids0.9%Gabapentin75%Pregabalin25%Part D≥49 patientsBenzodiazepine0.7%Clonazepam74%Alprazolam18%Diazepam8%Part D<11 patients+ 17 more classes in this area
Dermatology
3.2%Corticosteroid3.2%Methylprednisolone sodium succinate100%Part B, office-administered≥28 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Eye movement analysis during working memory tasks correlates with cognitive, clinical, and anatomical metrics in multiple sclerosis.
Multiple sclerosis journal - experimental, translational and clinical
Article2026 - Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.
Neurology(R) neuroimmunology & neuroinflammation
Clinical Trial2026 - Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion.
Neurology(R) neuroimmunology & neuroinflammation
Article2024
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated SyndromeArticle140 citations2022
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/gabriel-pardo-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
practicalneurology.com/profiles/gabriel-pardo-md-faan/OYAgMJ/biography
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →practicalneurology.com ↗
Mentions by others
where others cite or feature them- Other
omrf.org/tag/dr-gabriel-pardo
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →omrf.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →practicalneurology.com ↗
Editorial & leadership roles
journal and society appointments- Fellow
American Academy of Neurology (FAAN)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →practicalneurology.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →omrf.org ↗
Secondary affiliations
appointments beyond the home institution- Fellow
University of Texas Medical Branch at Galveston - Ophthalmology Fellowship
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →practicalneurology.com ↗ - Neurology Residency
University of Oklahoma Health Sciences Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →practicalneurology.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Joan Merrill, MD
Oklahoma Medical Research Foundation
Judith James, MD
Oklahoma Medical Research Foundation
Cristina Arriens, MD
Oklahoma Medical Research Foundation
Eliza Chakravarty, MD
Oklahoma Medical Research Foundation
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center